IDEXX Introduces the SNAPshot Dx™ Analyzer [Trade]

WESTBROOK, Maine, January 18, 2008—IDEXX Laboratories, Inc. (NASDAQ:IDXX), introduces the IDEXX SNAPshot Dx™, the next-generation endocrinology analyzer for the IDEXX VetLab® Suite. SNAPshot Dx enables veterinarians to run T4, cortisol and bile acids tests in-house quickly and conveniently. The new analyzer will be introduced at the North American Veterinary Conference (NAVC) in January of this year, and IDEXX will begin taking orders in February with shipments to start in March.

SNAPshot Dx will augment the IDEXX VetLab's ability to run a full profile within minutes by testing for T4 with either plasma or serum samples. This rapid capability supports the practice's screening and, if appropriate, treatment plan before patients leave the practice. Veterinary hospitals also will enjoy the benefits of running multiple patient samples simultaneously—increasing the availability of the instrument during busy periods. Activated SNAP® ELISA tests are simply inserted into either of two ports, and the analyzer then runs the assay and reads the results, automatically adding the data to the patient record in IDEXX VetLab® Station and incorporating the information into the results printout.

IDEXX plans to expand the SNAPshot Dx's menu later this year by adding the ability to run the entire family of SNAP® tests, including SNAP® FIV/FeLV Combo, SNAP® 4Dx®, SNAP® cPL™, SNAP® Giardia, and SNAP® Parvo. This new analyzer will add to the IDEXX VetLab a convenient, automated alternative to a manual interpretation of these kits, while automatically capturing the results in the patient's electronic record and the diagnostic results printout created by the IDEXX VetLab Station.

"With SNAPshot Dx, IDEXX offers veterinarians a new level of ease and efficiency when screening for hypothyroidism, hyperthyroidism, Cushing's syndrome, Addison's disease and liver disease in the hospital setting," said Michael Lane, Chemistry Marketing Director at IDEXX Laboratories. "Expanding this analyzer later this year to interpret and record the results of all SNAP devices will add further convenience to these ubiquitous kits and support the move to electronic medical records. By adding SNAPshot Dx to the IDEXX VetLab Suite we have not only increased in-house diagnostic capabilities, but further streamlined the workflow in everyday practices. Veterinarians will have the convenience of immediate results, but with less of their technician's time devoted to running lab work and with more time for patients and their owners."

For more information, go to www.idexx.com/snapshot or call IDEXX at 1-800-355-2896.

About IDEXX VetLab® Suite

The IDEXX VetLab Suite is a highly integrated set of veterinary analyzers that provides fast and flexible results on a patient's blood and urine within minutes of the pet visit. Diagnostic capabilities include clinical chemistry, electrolytes, hematology with five-part differential and reticulocytes, endocrinology, blood gases, and coagulation, urinalysis and infectious diseases. The IDEXX VetLab® Station, which serves as an information system for the in-house laboratory, uses the power of SmartLink™ technology to integrate results from all the analyzers—including the new Catalyst Dx™ and SNAPshot Dx™ Analyzers—and IDEXX SNAP® point-of-care tests into a single comprehensive and easy-to-use patient report and stores this information in its database for easy future reference and historical results-trending capability.

About IDEXX Laboratories

IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,500 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements

This press release contains statements about the Company's business that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company's sales and marketing activities; the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company's products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company's inventories; the Company's ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (PDF, 1.5 MB), and on the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 (PDF, 743 KB), in the section captioned "Risk Factors."